Free Republic
Browse · Search
General/Chat
Topics · Post Article

Skip to comments.

Scientists discovered a new molecule that kills even the deadliest cancer
Interesting Engineering ^ | 6.10.2022 | Deena Theresa

Posted on 06/12/2022 11:08:17 AM PDT by libh8er

Recently, a tiny group of people with rectal cancer saw their disease vanish after experimental treatment.

Now, in another breakthrough, a new compound synthesized by Dr. Jung-Mo Ahn, a University of Texas at Dallas researcher, has been found to kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, leaving healthy cells unscathed.

He exploited a weakness in cells that were hitherto not targeted by the other drugs.

The study, which was carried out in isolated cells, both in human cancer tissue and in human cancers grown in mice, was published in the journal Nature Cancer.

Only a few options for patients with triple-negative breast cancer

Ahn, a co-corresponding author of the study and a UT Dallas associate professor of chemistry and biochemistry in the School of Natural Sciences and Mathematics, has been working on small molecules that target protein-protein interactions in cells for more than a decade. Previously, he had developed potential therapeutic candidate compounds for treatment-resistant breast cancer and prostate cancer.

In his current research, Ahn and his colleagues tested a new compound he synthesized called ERX-41 for its effects on breast cancer cells - those that contained estrogen receptors (ERs) and those that do not.

Now, there are effective treatments for patients with ER-positive breast cancer, but only a few treatment options for patients with triple-negative breast cancer (TNBC) exist. It lacks receptors for estrogen, progesterone, and human epidermal growth factor 2. TNBC is known to affect women under 40 and has worse outcomes than other types of breast cancer.

"The ERX-41 compound did not kill healthy cells, but it wiped out tumor cells regardless of whether the cancer cells had estrogen receptors," Ahn said. "In fact, it killed the triple-negative breast cancer cells better than it killed the ER-positive cells.

"This was puzzling to us at the time. We knew it must be targeting something other than estrogen receptors in the TNBC cells, but we didn't know what that was."

Soon, the researchers discovered that ERX-41 binds to lysosomal acid lipase A (LIPA), a cellular protein. LIPA is found in a cell structure called the endoplasmic reticulum, an organelle that processes and folds proteins.

"For a tumor cell to grow quickly, it has to produce a lot of proteins, and this creates stress on the endoplasmic reticulum," Ahn said. "Cancer cells significantly overproduce LIPA, much more so than healthy cells. By binding to LIPA, ERX-41 jams the protein processing in the endoplasmic reticulum, which becomes bloated, leading to cell death."

The team tested the molecule in healthy mice and noted that there were no ill effects. "It took us several years to chase down exactly which protein was being affected by ERX-41. That was the hard part. We chased many dead ends, but we did not give up," Ahn said.

"Triple-negative breast cancer is particularly insidious - it targets women at younger ages; it's aggressive, and it's treatment-resistant. I'm really glad we've discovered something that has the potential to make a significant difference for these patients," Ahn said.

Can defeat the deadliest cancer

The researchers then fed the compound to mice with human forms of cancerous tumors, and they got smaller.

The molecule also killed cancer cells in human tissue that were gathered from patients who had their tumors removed.

There's more.

They found that ERX-41 is effective against other cancer types with elevated endoplasmic reticulum stress, including hard-to-treat pancreatic and ovarian cancers and glioblastoma, the most 'aggressive and lethal primary brain cancer'.

To investigate the ERX-41 molecule, Ahn worked with collaborators, including co-corresponding authors Dr. Ganesh Raj, professor of urology and pharmacology at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, as well as Dr. Ratna Vadlamudi, professor of obstetrics and gynecology at UT Health San Antonio. Dr. Tae-Kyung Lee, a former UTD research scientist in Ahn's Bio-Organic/Medicinal Chemistry Lab, was also involved in synthesizing the compound.

Ahn is a joint holder of patents issued and pending on ERX-41 and related compounds, which have been licensed to the Dallas-based startup EtiraRX, a company co-founded in 2018 by Ahn, Raj, and Vadlamudi. The company has announced that it plans to begin clinical trials of ERX-41 as early as the first quarter of 2023, which offers the hope of effective new treatments. to-treat cancers, including triple-negative breast cancer, leaving healthy cells unscathed.

He exploited a weakness in cells that were hitherto not targeted by the other drugs.

The study, which was carried out in isolated cells, both in human cancer tissue and in human cancers grown in mice, was published in the journal Nature Cancer.

Recently, a tiny group of people with rectal cancer saw their disease vanish after experimental treatment.

It was a very small trial done by doctors at New York's Memorial Sloan Kettering Cancer Center, wherein the patients took a drug called dostarlimab for six months. At the end of their trial, every single one of their tumors disappeared.

Now, in another breakthrough, a new compound synthesized by Dr. Jung-Mo Ahn, a University of Texas at Dallas researcher, has been found to kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, leaving healthy cells unscathed.

He exploited a weakness in cells that were hitherto not targeted by the other drugs.

The study, which was carried out in isolated cells, both in human cancer tissue and in human cancers grown in mice, was published in the journal Nature Cancer.

Only a few options for patients with triple-negative breast cancer

Ahn, a co-corresponding author of the study and a UT Dallas associate professor of chemistry and biochemistry in the School of Natural Sciences and Mathematics, has been working on small molecules that target protein-protein interactions in cells for more than a decade. Previously, he had developed potential therapeutic candidate compounds for treatment-resistant breast cancer and prostate cancer.

In his current research, Ahn and his colleagues tested a new compound he synthesized called ERX-41 for its effects on breast cancer cells - those that contained estrogen receptors (ERs) and those that do not.

Now, there are effective treatments for patients with ER-positive breast cancer, but only a few treatment options for patients with triple-negative breast cancer (TNBC) exist. It lacks receptors for estrogen, progesterone, and human epidermal growth factor 2. TNBC is known to affect women under 40 and has worse outcomes than other types of breast cancer.

"The ERX-41 compound did not kill healthy cells, but it wiped out tumor cells regardless of whether the cancer cells had estrogen receptors," Ahn said. "In fact, it killed the triple-negative breast cancer cells better than it killed the ER-positive cells.

"This was puzzling to us at the time. We knew it must be targeting something other than estrogen receptors in the TNBC cells, but we didn't know what that was."

Soon, the researchers discovered that ERX-41 binds to lysosomal acid lipase A (LIPA), a cellular protein. LIPA is found in a cell structure called the endoplasmic reticulum, an organelle that processes and folds proteins.

"For a tumor cell to grow quickly, it has to produce a lot of proteins, and this creates stress on the endoplasmic reticulum," Ahn said. "Cancer cells significantly overproduce LIPA, much more so than healthy cells. By binding to LIPA, ERX-41 jams the protein processing in the endoplasmic reticulum, which becomes bloated, leading to cell death."

The team tested the molecule in healthy mice and noted that there were no ill effects. "It took us several years to chase down exactly which protein was being affected by ERX-41. That was the hard part. We chased many dead ends, but we did not give up," Ahn said.

"Triple-negative breast cancer is particularly insidious - it targets women at younger ages; it's aggressive, and it's treatment-resistant. I'm really glad we've discovered something that has the potential to make a significant difference for these patients," Ahn said.

Can defeat the deadliest cancer

The researchers then fed the compound to mice with human forms of cancerous tumors, and they got smaller.

The molecule also killed cancer cells in human tissue that were gathered from patients who had their tumors removed.

There's more.

They found that ERX-41 is effective against other cancer types with elevated endoplasmic reticulum stress, including hard-to-treat pancreatic and ovarian cancers and glioblastoma, the most 'aggressive and lethal primary brain cancer'.

To investigate the ERX-41 molecule, Ahn worked with collaborators, including co-corresponding authors Dr. Ganesh Raj, professor of urology and pharmacology at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, as well as Dr. Ratna Vadlamudi, professor of obstetrics and gynecology at UT Health San Antonio. Dr. Tae-Kyung Lee, a former UTD research scientist in Ahn's Bio-Organic/Medicinal Chemistry Lab, was also involved in synthesizing the compound.

Ahn is a joint holder of patents issued and pending on ERX-41 and related compounds, which have been licensed to the Dallas-based startup EtiraRX, a company co-founded in 2018 by Ahn, Raj, and Vadlamudi. The company has announced that it plans to begin clinical trials of ERX-41 as early as the first quarter of 2023, which offers the hope of effective new treatments.


TOPICS: Health/Medicine
KEYWORDS: breastcancer; cancer; cancercells; cancerresearch; cancertherapy; dostarlimab; jemperli
Navigation: use the links below to view more comments.
first previous 1-2021-4041-6061-71 next last
To: guido911

Now we need a cure for DemocRATs.


21 posted on 06/12/2022 12:20:52 PM PDT by Howie66 (Let's Go Brandon!!)
[ Post Reply | Private Reply | To 2 | View Replies]

Comment #22 Removed by Moderator

To: Savage Beast

“As a physician, I have seen two cases of advanced cancer cured by prayer.”

As a scientist, I say that you have no proof.


23 posted on 06/12/2022 12:21:51 PM PDT by TexasGator (UF)
[ Post Reply | Private Reply | To 6 | View Replies]

To: libh8er; Shimmer1

Too late for some. Hope and survival for many.


24 posted on 06/12/2022 12:23:24 PM PDT by null and void (We're trapped between too many questions unanaswered, and too many answers unquestioned...)
[ Post Reply | Private Reply | To 1 | View Replies]

To: libh8er
https://communities.win/c/Conspiracies/p/12kFnAdfAW/ivermectin-cures-cancer-/

https://freerepublic.com/focus/f-chat/4035646/posts

https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7505114/
Ivermectin has powerful antitumor effects, including the inhibition of proliferation, metastasis, and angiogenic activity, in a variety of cancer cells. This may be related to the regulation of multiple signaling pathways by ivermectin through PAK1 kinase. On the other hand, ivermectin promotes programmed cancer cell death, including apoptosis, autophagy and pyroptosis. Ivermectin induces apoptosis and autophagy is mutually regulated. Interestingly, ivermectin can also inhibit tumor stem cells and reverse multidrug resistance and exerts the optimal effect when used in combination with other chemotherapy drugs.

Ran across all these cancer trials for Ivermectin. Maybe there was another big reason that they shutdown Ivermectin for Covid.
If it cured a lot of cancers, just think how much money the Big Pharma would lose on cancer treatments
Mary

The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC5835698/

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes
https://pubmed.ncbi.nlm.nih.gov/32549918/

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen
https://pubmed.ncbi.nlm.nih.gov/32533071/
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN)
https://clinicaltrials.gov/ct2/show/NCT04447235
The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells
https://ashpublications.org/blood/article/116/18/3593/27970/The-antiparasitic-agent-ivermectin-induces
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma
https://onlinelibrary.wiley.com/doi/10.1111/jcmm.15195
Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations
https://www.nature.com/articles/ja201711

https://communities.win/c/Conspiracies/p/12kFnAdfAW/ivermectin-cures-cancer-/

https://freerepublic.com/focus/f-chat/4035646/posts

25 posted on 06/12/2022 12:27:19 PM PDT by FR_addict
[ Post Reply | Private Reply | To 1 | View Replies]

To: guido911

My sister has been fighting breast cancer for years—years. It eventually breached brain barrier and things were not looking good. She got into a study with new drug, and within months was cancer free. Things are turning. I can feel it

Wow. That’s wonderful.


26 posted on 06/12/2022 12:30:58 PM PDT by Flick Lives (The CDC. Brought to you by Pfizer)
[ Post Reply | Private Reply | To 11 | View Replies]

To: libh8er

Bttt


27 posted on 06/12/2022 12:33:13 PM PDT by nikos1121
[ Post Reply | Private Reply | To 1 | View Replies]

To: CaptainK

28 posted on 06/12/2022 12:38:30 PM PDT by Lazamataz (The firearms I own today, are the firearms I will die with. How I die will be up to them.)
[ Post Reply | Private Reply | To 19 | View Replies]

To: FR_addict

I wondered how long it would take the physician hating ivermectin cross to show up.


29 posted on 06/12/2022 12:43:11 PM PDT by Mom MD ( )
[ Post Reply | Private Reply | To 25 | View Replies]

To: guido911

They wont let this get to far cant have the cancer fund dry up because of a new cure follow the money.


30 posted on 06/12/2022 12:45:42 PM PDT by bikerman (BLUE LIVES MATTER, FJB.)
[ Post Reply | Private Reply | To 2 | View Replies]

To: Dutch Boy
I hope they are real and not yet another distraction.

The $10,000.00 a shot is real for sure.

31 posted on 06/12/2022 12:51:39 PM PDT by itsahoot (Many Republicans are secretly Democrats, no Democrats are secretly Republicans. Dan Bongino.)
[ Post Reply | Private Reply | To 7 | View Replies]

To: libh8er

Too bad they didn’t find this out before my beautiful 36 year old sister died of it leaving two small children behind.


32 posted on 06/12/2022 12:53:42 PM PDT by Georgia Girl 2 (The only purpose of a pistol is to fight your way back to the rifle you should never have dropped)
[ Post Reply | Private Reply | To 1 | View Replies]

To: libh8er

It’s nice to know that there are still scientists performing science.


33 posted on 06/12/2022 12:54:17 PM PDT by voicereason (The RNC is like the "one-night stand" you wish you could forget.)
[ Post Reply | Private Reply | To 1 | View Replies]

To: Mom MD; FR_addict
I wondered how long it would take the physician hating ivermectin cross to show up.

Put you mask back on mom.

34 posted on 06/12/2022 12:56:17 PM PDT by itsahoot (Many Republicans are secretly Democrats, no Democrats are secretly Republicans. Dan Bongino.)
[ Post Reply | Private Reply | To 29 | View Replies]

To: JimRed

“What are the not-yet-stated side effects?”

You eventually die of old age.


35 posted on 06/12/2022 12:56:32 PM PDT by Larry Lucido (Donate! Don't just post clickbait!)
[ Post Reply | Private Reply | To 14 | View Replies]

To: itsahoot

Don’t wear one. Any other incorrect assumptions you would like to air?


36 posted on 06/12/2022 12:58:22 PM PDT by Mom MD ( )
[ Post Reply | Private Reply | To 34 | View Replies]

To: libh8er

Looking at the structure of ERX-41: no structural elements present that seem to be able to cause toxicity; confirmed by authors observation that it’s not toxic for mammals. Good-looking molecule, hope the efficacy is decent…


37 posted on 06/12/2022 1:00:00 PM PDT by exinnj
[ Post Reply | Private Reply | To 1 | View Replies]

To: libh8er

Judging crime reports of the last few weeks cancer is totally on the ropes and high capacity fast charge batteries are the coming thing.


38 posted on 06/12/2022 1:04:20 PM PDT by TalBlack (We have a Christian duty and a patriotic duty. God help us.)
[ Post Reply | Private Reply | To 1 | View Replies]

To: libh8er

PFL


39 posted on 06/12/2022 1:08:01 PM PDT by Magic Fingers (Political correctness mutates in order to remain virulent.)
[ Post Reply | Private Reply | To 1 | View Replies]

To: TalBlack

Judging FROM reports…


40 posted on 06/12/2022 1:08:53 PM PDT by TalBlack (We have a Christian duty and a patriotic duty. God help us.)
[ Post Reply | Private Reply | To 38 | View Replies]


Navigation: use the links below to view more comments.
first previous 1-2021-4041-6061-71 next last

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
General/Chat
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson